Adc Therapeutics SA
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.29%.
Did ADCT Beat Earnings? Q2 2025 Results
ADC Therapeutics delivered a mixed but strategically eventful second quarter, beating revenue expectations while posting a wider GAAP loss tied to a sweeping restructuring effort. The Swiss oncology company reported Q2 2025 revenue of $18.84 million, up 8.2% year-over-year and ahead of the $17.86 million consensus estimate, driven by higher net sales pricing for its lymphoma therapy ZYNLONTA. On an adjusted basis, the net loss came in at $0.25 per share, though the GAAP loss deepened to $0.50 per share as $13.09 million in restructuring charges, stemming from a strategic reprioritization that includes a roughly 30% workforce reduction and the closure of its UK facility, weighed heavily on results. Shares have nonetheless climbed 34.7% year-to-date, reflecting investor confidence in the clinical pipeline; LOTIS-7 data showed a 93.3% overall response rate for ZYNLONTA plus glofitamab in relapsed/refractory DLBCL. A completed $100 million private placement extended the company's cash runway into 2028, with a potential sBLA submission for ZYNLONTA targeted for the first half of 2026.
- Higher ZYNLONTA sales price partially offset by variable sales volume
- Increased R&D spending driven by LOTIS-5 and LOTIS-7 enrollment and PSMA ADC IND-enabling activities
- Restructuring, impairment and related costs of $13.1 million in Q2 2025
- Lower selling and marketing expenses due to reduced marketing and advertising spend
- Lower G&A expenses due to reduced external professional fees
“Entering the second half of 2025, we have streamlined our strategic focus and strengthened our financial foundation, which now allows us to pursue multiple promising opportunities to expand ZYNLONTA® into earlier lines of therapy in DLBCL and indolent lymphomas.”
ADC Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
ADC Therapeutics expects LOTIS-5 to reach its prespecified PFS event target by end of 2025, with topline data to follow. A potential sBLA submission for ZYNLONTA in 2L+ DLBCL is anticipated in the first half of 2026, with potential confirmatory approval and publication/compendia inclusion in the first half of 2027. The LOTIS-7 trial is expanding to 100 r/r DLBCL patients with additional data expected in H2 2025, and the company plans FDA engagement on this trial. IND-enabling activities for the PSMA-targeting ADC are expected to be completed by end of 2025. The $100 million PIPE financing extends the company's expected cash runway into 2028. The strategic restructuring, including UK facility closure and approximately 30% workforce reduction, is expected to be substantially completed by September 30, 2025.
ADCT YoY Financials
ADCT Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.